Acorda Therapeutics Supplements the Tender Offer Document Relating to the Voluntary Public Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. on 22 March 2016

ARDSLEY, N.Y.–(BUSINESS WIRE)– As announced on 10 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR)
(« Acorda » or the « Offeror« ) has on 11 March
2016 commenced a voluntary public tender offer (the « Tender Offer« )
to purchase all of the issued and outstanding shares (« Shares« ),
American Depositary Shares (« ADSs« ), stock options (« Option
Rights« ), share units (« Share Rights« ) and warrants
(« Warrants« ) in Biotie Therapies Corp. (Nasdaq Helsinki:
BTH1V;Nasdaq: BITI) (« Biotie » or the « Company« )
that are not owned by Biotie or any of its subsidiaries.

Biotie published its audited financial statement report for the
financial year ended 31 December 2015 (« 2015 Financial Statement
Report« ) on 22 March 2016. As set forth in Supplement No. 2 to the
Tender Offer Document (“Supplement No. 2”), attached as Annex 1
of this release, Acorda supplements the Tender Offer Document with the
2015 Financial Statement Report, which is attached as Annex 2 of this
release and included as Annex I of the Tender Offer Document.

The Tender Offer Document, together with Supplement No. 1 and Supplement
No. 2, is available in Finnish at the branch offices of the cooperative
bank belonging to the OP Financial Group or Helsinki OP Bank Ltd. and at
Nasdaq Helsinki, Fabianinkatu 14, FI-00130 Helsinki, Finland, at the
offices of the Offeror at Office of the Corporate Secretary, 420 Saw
Mill River Road, Ardsley, NY, 10502 and on the internet at www.op.fi/merkinta,
http://ir.acorda.com/investors/Biotie-Therapies-Tender-Offer/default.aspx
and www.biotie.com/sijoittajat.

Annex 1: Supplement No. 2 to the Tender Offer Document

Annex 2: 2015 Financial Statement Report of Biotie Therapies Corp.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that restore function and improve the lives of
people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson’s disease,
epilepsy, post-stroke walking deficits, migraine, and multiple
sclerosis. Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

For more information, please visit www.acorda.com.

About Biotie Therapies

Biotie is a biopharmaceutical company focused on products for
neurodegenerative and psychiatric disorders. Biotie’s development has
delivered Selincro (nalmefene) for alcohol dependence, which received
European marketing authorization in 2013 and is currently being rolled
out across Europe by partner H. Lundbeck A/S. The current development
products include tozadenant for Parkinson’s disease, which is in Phase 3
development, and two additional compounds which are in Phase 2
development for cognitive disorders including Parkinson’s disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic
disease of the liver.

For more information, please visit www.biotie.com.

Forward-Looking Statements

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to complete the Biotie transaction on a timely basis or at all;
the ability to realize the benefits anticipated from the Biotie and
Civitas transactions, among other reasons because acquired development
programs are generally subject to all the risks inherent in the drug
development process and our knowledge of the risks specifically relevant
to acquired programs generally improves over time; the ability to
successfully integrate Biotie’s operations and Civitas’ operations,
respectively, into our operations; we may need to raise additional funds
to finance our expanded operations and may not be able to do so on
acceptable terms; our ability to successfully market and sell Ampyra in
the U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other acquired
or in-licensed programs; we may not be able to complete development of,
obtain regulatory approval for, or successfully market CVT-301, Plumiaz,
any other products under development, or the products that we would
acquire if we complete the Biotie transaction; the occurrence of adverse
safety events with our products; delays in obtaining or failure to
obtain and maintain regulatory approval of or to successfully market
Fampyra outside of the U.S. and our dependence on our collaborator
Biogen in connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and failure to comply
with regulatory requirements could result in adverse action by
regulatory agencies.

Additional Information

Investors and holders of Biotie equity securities are strongly advised
to read the tender offer statement, including the offer to purchase,
letter of transmittal, acceptance forms and other related tender offer
documents and the related solicitation/recommendation statement on
Schedule 14D-9 that have been filed by Biotie with the SEC, because
contain important information. These documents are available at no
charge on the SEC’s website at www.sec.gov.
In addition, a copy of the Tender Offer Document and related documents
may be obtained free of charge by directing a request to us at www.acorda.com
or Office of the Corporate Secretary, 420 Saw Mill River Road, Ardsley,
New York 10502.

In addition to the Schedule TO, we file annual, quarterly and special
reports, proxy statements and other information with the SEC. You may
read and copy any reports, statements or other information filed by us
at the SEC public reference room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. Our filings with the SEC are also available
to the public from commercial document-retrieval services and at the
website maintained by the SEC at www.sec.gov.

THE TENDER OFFER WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY
JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS
PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR
REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE
UNDERTAKEN IN FINLAND AND THE UNITED STATES.

IN ADDITION, THE TENDER OFFER DOCUMENT, THE RELATED DOCUMENTS AND
THIS RELEASE WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR
TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE
LAW. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR
INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG
KONG. THE TENDER OFFER CANNOT BE ACCEPTED BY ANY SUCH USE, MEANS OR
INSTRUMENTALITY OR FROM WITHIN CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR
HONG KONG.

This release is for informational purposes only and does not constitute
a tender offer document or an offer, solicitation of an offer or an
invitation to a sales offer. Potential investors in Finland shall accept
the Tender Offer only on the basis of the information provided in the
tender offer document, as supplemented, approved by the Finnish
Financial Supervisory Authority and related materials.

ANNEX 1: SUPPLEMENT NO. 2 TO THE TENDER OFFER DOCUMENT

SUPPLEMENT NO. 2 TO THE TENDER OFFER DOCUMENT ISSUED ON 11 MARCH 2016
BY ACORDA THERAPEUTICS, INC. RELATING TO THE VOLUNTARY PUBLIC TENDER
OFFER FOR ALL OF THE ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY
SHARES, STOCK OPTIONS, SHARE UNITS AND WARRANTS IN BIOTIE THERAPIES OYJ

22 March 2016

Acorda Therapeutics, Inc. (« Acorda« ) supplements the tender
offer document published on 11 March 2016 (« Tender Offer Document« )
in accordance with the Chapter 11, Section 11, Subsection 4 of the
Finnish Securities Markets Act (746/2012, fi: Arvopaperimarkkinalaki)
as follows.

Biotie Therapies Corp. (« Biotie« ) published its audited
financial statement report for the financial year ended 31 December 2015
(« 2015 Financial Statement Report« ) on 22 March 2016. Acorda
supplements Section 5.10 of the Tender Offer Document with the 2015
Financial Statement Report, which is added as Annex I of the Tender
Offer Document.

The Tender Offer Document with the aforementioned supplements and
amendments is available from 22 March 2016.

The Finnish Financial Supervisory Authority has approved the Finnish
language version of this supplement but is not responsible for the
accuracy of the information presented therein. The decision number of
such approval is FIVA 4/02.05.05/2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160322005754/en/